Emerging therapies and challenges in spinal muscular atrophy
Open Access
- 17 February 2017
- journal article
- review article
- Published by Wiley in Annals of Neurology
- Vol. 81 (3), 355-368
- https://doi.org/10.1002/ana.24864
Abstract
Spinal muscular atrophy (SMA) is a hereditary neurodegenerative disease with severity ranging from progressive infantile paralysis and premature death (type I) to limited motor neuron loss and normal life expectancy (type IV). Without disease-modifying therapies, the impact is profound for patients and their families. Improved understanding of the molecular basis of SMA, disease pathogenesis, natural history, and recognition of the impact of standardized care on outcomes has yielded progress toward the development of novel therapeutic strategies and are summarized. Therapeutic strategies in the pipeline are appraised, ranging from SMN1 gene replacement to modulation of SMN2 encoded transcripts, to neuroprotection, to an expanding repertoire of peripheral targets, including muscle. With the advent of preliminary trial data, it can be reasonably anticipated that the SMA treatment landscape will transform significantly. Advancement in presymptomatic diagnosis and screening programs will be critical, with pilot newborn screening studies underway to facilitate preclinical diagnosis. The development of disease-modifying therapies will necessitate monitoring programs to determine the long-term impact, careful evaluation of combined treatments, and further acceleration of improvements in supportive care. In advance of upcoming clinical trial results, we consider the challenges and controversies related to the implementation of novel therapies for all patients and set the scene as the field prepares to enter an era of novel therapies. Ann Neurol 2017Funding Information
- Muscular Dystrophy UK
- National Health and Medical Research Council (1104299)
- National Institutes of Health
This publication has 102 references indexed in Scilit:
- Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse modelNature, 2011
- Dysfunction of axonal membrane conductances in adolescents and young adults with spinal muscular atrophyBrain, 2011
- Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimensEuropean Journal of Human Genetics, 2011
- Temporal requirement for high SMN expression in SMA miceHuman Molecular Genetics, 2011
- Interaction of survival of motor neuron (SMN) and HuD proteins with mRNA cpg15 rescues motor neuron axonal deficitsProceedings of the National Academy of Sciences of the United States of America, 2011
- RETRACTED ARTICLE: Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMNNature Biotechnology, 2010
- Effects of 2,4-diaminoquinazoline derivatives on SMN expression and phenotype in a mouse model for spinal muscular atrophyHuman Molecular Genetics, 2009
- A Positive Modifier of Spinal Muscular Atrophy in the SMN2 GeneAmerican Journal of Human Genetics, 2009
- Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?Nature Reviews Neuroscience, 2009
- Bone loss in survival motor neuron (Smn−/−SMN2) genetic mouse model of spinal muscular atrophyThe Journal of Pathology, 2009